Finance
Gene-based therapies company reports second quarter 2005 financial results
Published in Gene Therapy Weekly, September 8th, 2005
For the quarter ended June 30, 2005, Sirna reported a net loss applicable to common stock of $5.9 million, or $0.14 per share, compared to a net loss applicable to common stock of $6.3 million, or $0.18 per share, for the same period in 2004.
Sirna ended the second quarter with $18.7 million in cash and marketable securities. Subsequently, on July 5, the company entered into definitive agreements for the sale of common stock and warrants in a private placement for aggregate gross proceeds of $28 million. Revenues for the second quarter of 2005 were...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2005-09-08)
More Articles from Gene Therapy Weekly
- Colon Cancer
Genetic screen for candidate tumor suppressors identified REST - Gene Research
Company expands RNAi product line to 50,000 in frozen or plasmid DNA form - Muscular Dystrophy
No small feat: First ever gene therapy success for muscular dystrophy achieved - Parkinson Disease
Continuous delivery of GDNF optimizes neural transplantation therapy - Transplant Medicine
Akt a target for islet transplantation strategies in diabetics - Acute Myeloid Leukemia
Antiangiogenic treatment with endostatin successfully fights AML - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
